Stephen Donelan, MD
Nephrology · State College, PANPI 1417910605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Boehringer Ingelheim at 42.9% of the total. 2025 is the largest year on record at $148, 4.7 times the $31 reported in 2023. That places this record below the midpoint for nephrology clinicians in PA, where the typical reported total is $612.
Across 14 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$111
- Otsuka America Pharmaceutical, Inc.$61
- AstraZeneca$37
- Amgen$18
- Fresenius USA Marketing, Inc.$18
- Merck$14
What the payments were for
- Food & beverage$260100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $111 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| AstraZeneca | 2 | $37 |
| Amgen | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Merck | 1 | $14 |
How this compares
$260 in reported general payments places this provider in the 30th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bumetanide | 61 | $3,044 |
| Potassium Chloride | 36 | $2,332 |
| HyzaarLosartan/Hydrochlorothiazide | 13 | $1,745 |
| Labetalol Hcl | 18 | $1,650 |
| Potassium Citrate ErPotassium Citrate | 20 | $1,566 |
| Amlodipine Besylate | 139 | $1,490 |
| Calcitriol | 34 | $1,064 |
| Metoprolol Succinate | 35 | $951 |
| Chlorthalidone | 32 | $872 |
| Lisinopril | 75 | $848 |
| Hydralazine Hcl | 46 | $831 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $761 |
| Furosemide | 160 | $744 |
| Losartan Potassium | 81 | $720 |
| Allopurinol | 32 | $700 |
Paid to pharmacies, not to this prescriber.
Other nephrology in State College
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.